164 related articles for article (PubMed ID: 24265799)
1. Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity.
Han X; Xu Y; Yang Y; Xi J; Tian W; Duggineni S; Huang Z; An J
PLoS One; 2013; 8(11):e80183. PubMed ID: 24265799
[TBL] [Abstract][Full Text] [Related]
2. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
[TBL] [Abstract][Full Text] [Related]
3. Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling.
Bowden TA; Aricescu AR; Nettleship JE; Siebold C; Rahman-Huq N; Owens RJ; Stuart DI; Jones EY
Structure; 2009 Oct; 17(10):1386-97. PubMed ID: 19836338
[TBL] [Abstract][Full Text] [Related]
4. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.
Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB
Biochem J; 2012 Jul; 445(1):47-56. PubMed ID: 22489865
[TBL] [Abstract][Full Text] [Related]
5. Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.
Guo FY; Lesk AM
Proteins; 2014 Mar; 82(3):349-53. PubMed ID: 24105818
[TBL] [Abstract][Full Text] [Related]
6. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity.
Qin H; Noberini R; Huan X; Shi J; Pasquale EB; Song J
J Biol Chem; 2010 Jan; 285(1):644-54. PubMed ID: 19875447
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.
Noberini R; Koolpe M; Lamberto I; Pasquale EB
Pharmacol Res; 2012 Oct; 66(4):363-73. PubMed ID: 22750215
[TBL] [Abstract][Full Text] [Related]
9. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5.
Xu K; Tzvetkova-Robev D; Xu Y; Goldgur Y; Chan YP; Himanen JP; Nikolov DB
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14634-9. PubMed ID: 23959867
[TBL] [Abstract][Full Text] [Related]
10. Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4.
Royet A; Broutier L; Coissieux MM; Malleval C; Gadot N; Maillet D; Gratadou-Hupon L; Bernet A; Nony P; Treilleux I; Honnorat J; Liebl D; Pelletier L; Berger F; Meyronet D; Castets M; Mehlen P
Oncotarget; 2017 Apr; 8(14):23750-23759. PubMed ID: 28423606
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
12. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
13. EphA4 signaling regulates phospholipase Cgamma1 activation, cofilin membrane association, and dendritic spine morphology.
Zhou L; Martinez SJ; Haber M; Jones EV; Bouvier D; Doucet G; Corera AT; Fon EA; Zisch AH; Murai KK
J Neurosci; 2007 May; 27(19):5127-38. PubMed ID: 17494698
[TBL] [Abstract][Full Text] [Related]
14. Potent and Selective EphA4 Agonists for the Treatment of ALS.
Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M
Cell Chem Biol; 2017 Mar; 24(3):293-305. PubMed ID: 28196613
[TBL] [Abstract][Full Text] [Related]
15. Targeting the EphA4 receptor in the nervous system with biologically active peptides.
Murai KK; Nguyen LN; Koolpe M; McLennan R; Krull CE; Pasquale EB
Mol Cell Neurosci; 2003 Dec; 24(4):1000-11. PubMed ID: 14697664
[TBL] [Abstract][Full Text] [Related]
16. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors.
Noberini R; De SK; Zhang Z; Wu B; Raveendra-Panickar D; Chen V; Vazquez J; Qin H; Song J; Cosford ND; Pellecchia M; Pasquale EB
Chem Biol Drug Des; 2011 Oct; 78(4):667-78. PubMed ID: 21791013
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations.
Singla N; Goldgur Y; Xu K; Paavilainen S; Nikolov DB; Himanen JP
Biochem Biophys Res Commun; 2010 Sep; 399(4):555-9. PubMed ID: 20678482
[TBL] [Abstract][Full Text] [Related]
18. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs.
Gu S; Fu WY; Fu AKY; Tong EPS; Ip FCF; Huang X; Ip NY
Sci Rep; 2018 May; 8(1):7377. PubMed ID: 29743517
[TBL] [Abstract][Full Text] [Related]
19. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Saintigny P; Peng S; Zhang L; Sen B; Wistuba II; Lippman SM; Girard L; Minna JD; Heymach JV; Johnson FM
Mol Cancer Ther; 2012 Sep; 11(9):2021-32. PubMed ID: 22807579
[TBL] [Abstract][Full Text] [Related]
20. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
